Compare GSK plc (GSK) vs Centrus Energy Corp (LEU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Centrus Energy Corp — how do they compare? GSK plc trades at $46.5 (market cap $91.88B), while Centrus Energy Corp trades at $142.44 (market cap $2.91B). The key difference: GSK plc is far larger — about 31.6× Centrus Energy Corp's market cap, and GSK plc pays a 3.9% dividend while Centrus Energy Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Centrus Energy Corp for 29 Days on average.
| GSK | LEU | |
|---|---|---|
Market Cap | $91.88B | $2.91B |
Volume | 7,730,529 | 903,777 |
Sector | Health | Energy |
52-Week High | $61.18 | $436.00 |
52-Week Low | $43.24 | $138.18 |
Typical Hold Time | 93 Days | 29 Days |
Enterprise Value | $111.88B | $2.22B |
Dividend Yield | 3.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.54, down 1.02% with bearish technical signals but strong fundamentals including 29.73% ROE and consistent earnings beats. The company maintains robust profitability with 72.73% gross margins and is actively expanding its oncology pipeline through strategic partnerships. Recent developments include a $750M cancer therapy acquisition and advancing mRNA vaccine candidates.
GSK presents a mixed outlook with strong operational performance offset by technical weakness. Investment appeal lies in valuation multiples below industry averages and pipeline expansion, though risks include HIV patent expirations and manufacturing restructuring. Analyst consensus leans cautious with 55% hold ratings amid near-term headwinds.
Centrus Energy (LEU) trades at $142.09, down 3.43% on the day, with technical indicators showing a bearish trend. The company reported mixed quarterly results, missing Q4 2025 EPS estimates but beating in Q1 and Q2 2026. Recent news highlights Centrus as a key player in the nuclear fuel supply chain, securing multiple HALEU contracts amid growing nuclear energy demand. Valuation metrics appear elevated with a P/E of 75.18 and P/S of 6.68, while profitability metrics show a net income margin of 10.23% and ROE of 8.05%.
The outlook for LEU is cautiously optimistic, supported by strategic positioning in the nuclear fuel market and recent contract wins. However, high valuation multiples and recent earnings volatility present risks. Analyst consensus is mixed with 46% buy ratings and a $218.10 price target, suggesting potential upside if execution improves. Key risks include execution challenges, competitive pressures, and dependence on nuclear energy policy support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Centrus Energy Corp
Centrus Energy is a leading supplier of nuclear fuel and services for the global power industry. It specializes in supplying low-enriched uranium and developing next-generation fuels for advanced nuclear reactors.
Read more on LEU →
